The collaboration leverages Resonant's proprietary IMPaCT tumor microenvironment model and target validation platform, which earned them a Johnson and Johnson Innovation - JLABS @ TMC QuickFire Challenge award in 2016, and Janssen industry-leading oncology capabilities to rapidly advance new targets and therapeutic opportunities.
Specific details of the agreement were not disclosed.
Resonant exploits its proprietary IMPaCT tumor microenvironment model and data platform to discover novel, unappreciated targets and functionally active anti-tumor antibodies for difficult to treat tumors.
Its live cell, function-first approach lets the tumor cells, microenvironment, and live animal immune systems do the work of target and therapeutic candidate identification and validation.
Resonant's models are based in part on technology developed in the laboratory of Dr. Steve Weiss in the Life Sciences Institute at the University of Michigan in Ann Arbor.
The platform has undergone several years of optimisation, resulting in an industrialised process and the establishment of a broad pipeline of novel monoclonal antibody therapeutic candidates.
The company is a resident of Johnson and Johnson Innovation, JLABS, a life science incubator program. Resonant has received institutional funding from Mercury Fund (headquartered in Houston) and MINTS (Ann Arbor).
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886